- Conditions
- Stable Angina
- Interventions
- Erenumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo, Erenumab PFS, Erenumab AI/Pen
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Long Beach, California • National City, California + 36 more
- Conditions
- Migraine
- Interventions
- AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Englewood, Colorado • Stamford, Connecticut + 11 more
- Conditions
- Headache, Migraine
- Interventions
- Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Anaheim, California • Cypress, California • Dallas, Texas + 1 more
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 955 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Anaheim, California • Encino, California + 55 more
- Conditions
- Migraine
- Interventions
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 38
- States / cities
- San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
- Conditions
- Migraine
- Interventions
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 38
- States / cities
- San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo, PACAP-38 Challenge Agent
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Anaheim, California